AIMC Topic: Muscular Atrophy, Spinal

Clear Filters Showing 1 to 9 of 9 articles

Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy.

Cellular and molecular life sciences : CMLS
AIM: The availability of disease-modifying therapies and newborn screening programs for spinal muscular atrophy (SMA) has generated an urgent need for reliable prognostic biomarkers to classify patients according to disease severity. We aim to identi...

Machine learning-enhanced electrical impedance myography to diagnose and track spinal muscular atrophy progression.

Physiological measurement
To evaluate electrical impedance myography (EIM) in conjunction with machine learning (ML) to detect infantile spinal muscular atrophy (SMA) and disease progression.. Twenty-six infants with SMA and twenty-seven healthy infants had been enrolled and ...

An interpretable data-driven prediction model to anticipate scoliosis in spinal muscular atrophy in the era of (gene-) therapies.

Scientific reports
5q-spinal muscular atrophy (SMA) is a neuromuscular disorder (NMD) that has become one of the first 5% treatable rare diseases. The efficacy of new SMA therapies is creating a dynamic SMA patient landscape, where disease progression and scoliosis dev...

From data to discovery: AI-guided analysis of disease-relevant molecules in spinal muscular atrophy (SMA).

Human molecular genetics
Spinal Muscular Atrophy is caused by partial loss of survival of motoneuron (SMN) protein expression. The numerous interaction partners and mechanisms influenced by SMN loss result in a complex disease. Current treatments restore SMN protein levels t...

Gait-assisted exoskeletons for children with cerebral palsy or spinal muscular atrophy: A systematic review.

NeuroRehabilitation
BACKGROUND: Cerebral Palsy (CP) and Spinal Muscular Atrophy (SMA) are common causes of motor disability in childhood. Gait exoskeletons are currently being used as part of rehabilitation for children with walking difficulties.